Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has been given a consensus recommendation of “Buy” by the ten analysts that are presently covering the stock, MarketBeat.com reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $43.43.
Several equities analysts recently issued reports on SYRE shares. Wedbush began coverage on Spyre Therapeutics in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $45.00 price target on the stock. Evercore ISI began coverage on Spyre Therapeutics in a report on Tuesday, July 16th. They issued an “outperform” rating on the stock.
Check Out Our Latest Analysis on SYRE
Institutional Trading of Spyre Therapeutics
Spyre Therapeutics Trading Down 1.0 %
SYRE stock opened at $32.43 on Tuesday. The company has a market capitalization of $1.31 billion, a P/E ratio of -0.45 and a beta of 2.92. The business has a 50 day simple moving average of $28.25 and a 200-day simple moving average of $30.47. Spyre Therapeutics has a twelve month low of $8.43 and a twelve month high of $47.97.
Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.04. Research analysts predict that Spyre Therapeutics will post -3.68 EPS for the current fiscal year.
Spyre Therapeutics Company Profile
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
Read More
- Five stocks we like better than Spyre Therapeutics
- 3 REITs to Buy and Hold for the Long Term
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- How to Capture the Benefits of Dividend Increases
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- There Are Different Types of Stock To Invest In
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.